Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07443202) titled 'Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)' on Feb. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Tarsus Pharmaceuticals, Inc.
Condition:
Ocular Rosacea
Intervention:
Drug: lotilaner
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: December 5, 2025
Target Sample Size: 155
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/stu...